Drugs / ZW191
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06555744 | Oct 2024 → Dec 2026 expected | cancer | Zymeworks BC Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Zymeworks BC Inc. | Results Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 zymeworks.com ↗
today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. |
| 2026-03-30 | Zymeworks BC Inc. | Regulatory Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate zymeworks.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC). |
| 2025-10-23 | Zymeworks BC Inc. | Results Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference zymeworks.com ↗ |
| 2024-07-22 | Zymeworks BC Inc. | Regulatory Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate zymeworks.com ↗ |
| 2023-04-18 | Zymeworks BC Inc. | Results Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting zymeworks.com ↗
ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZW191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06555744 ↗ |
| Modality | Other / unclassified | “a Folate Receptor Alpha Antibody Drug Conjugate, ZW191” NCT06555744 ↗ |
| Route | Intravenous | “Administered intravenously” NCT06555744 ↗ |